Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab + azacitidine in intermediate/high/very high risk MDS and CMML-2
NCT04266301Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jun 2020
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 36
01
Overview
A Phase 3 trial of sabatolimab in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Novartis. Started Jun 2020; status: terminated.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04266301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04266301.